Prostate Cancer

Drug-related hematological treatment-emergent adverse events were proportionately similar between the EBRT cohort and the those who did not receive EBRT to the bone.

"These data really show that even in the patients who upgrade and have more severe disease than were initially expected, even if their surgery was delayed for 12 months after having this upgraded diagnosis, these patients did just as well from a recurrence perspective, compared to patients who got surgery right away," says Kevin Shee, MD, PhD.

The expert panel concludes their discussion with a look toward the future of prostate cancer treatment and the evolving role of rectal spacers.

Data showed that treatment with radical prostatectomy was associated with worse urinary incontinence but not worse sexual function compared with other treatment options, regardless of cancer risk.

"Many men are quite reluctant to go to a specialist, specifically the urologist, because of the fear or reluctance to undergo an invasive test, [such as] a rectal exam," says Shahrokh F. Shariat, MD.

Patients were less likely to choose active surveillance when their decision was influenced by their treatment goals of achieving “cure” or to “live longer,” or when they perceived their diagnosis of low-risk prostate cancer to be more serious.

"We investigated and compared the risk of infection after transperineal MRI-targeted biopsy vs a transrectal MRI-targeted biopsy," says Jim C. Hu, MD, MPH.

"In deciding whom to discharge within hours of a less invasive but major surgery, we must ask ourselves which master we are serving: the insurer, the administrator, or our own ego," writes Badar M. Mian, MD.

"I tried to cover the focal therapies, at least just review some of the new ones that are coming in, even though they're still not necessarily 100% mainstream," says Andrew L. Siegel, MD.

A group of urologists and radiation oncologists detail how they were trained on the utilization of rectal spacers and offer practical advice for other clinicians treating patients with prostate cancer.

The panel provides clinical insights on the placement of rectal spacers, the management of toxicities, and the counseling of patients with prostate cancer following rectal spacer placement.

"In our multivariate analysis, we actually found that there was no significant difference between the groups," says Kevin Shee, MD, PhD.

In this companion article, Jaideep S. Sohi, MD, shares insights on PSMA-PET imaging’s impact on real-world diagnosis and management of prostate cancer.

"It's no surprise that there are many people interested in active surveillance and how we can be doing it better," says Kevin Shee, MD, PhD.

"This is just another way that we can exploit the body's own natural system to take care of cancer," says Daniel P. Petrylak, MD.

Neeraj Agarwal, MD, discusses an analysis from the phase 3 TITAN trial that explored the correlation between PSA response and survival among patients with metastatic castration-sensitive prostate cancer receiving apalutamide.

Urologists and radiation oncologists discuss the multidisciplinary approach to treating patients with prostate cancer and how they address treatment complications.

A detailed overview of clinical trials and ongoing research in prostate cancer investigating rectal spacers.

The phase 1/2 study is scheduled to commence in the first half of 2024.

The combination is approved for the treatment of patients with metastatic castration-resistant prostate cancer, regardless of mutation status.

The study is enrolling patients with relapsed/refractory metastatic castration-resistant prostate cancer who have received at least 1 next-generation androgen receptor pathway inhibitor.

The phase 1/2a CYPIDES trial assessed the safety and preliminary efficacy of ODM-208 in heavily pretreated patients with metastatic castration-resistant prostate cancer.

"I find writing kind of relaxing. I like it like I like sitting down and reading for an hour," says Andrew L. Siegel, MD.

The payment rate for the prostate cancer test went into effect on January 1, 2024.

Prostate cancer specialists outline the pros and cons of the rectal spacer options for patients with prostate cancer and discuss factors that influence spacer choice.

The expert panel outlines visibility considerations with the 3 rectal spacer options when treating patients with prostate cancer with radiation therapy.

The open-label CaRe PC trial plans to enroll up to 30 adult patients with mCRPC, who will be treated across 3 dose levels of INKmune.

"Nowadays, the complexity of potential management options have gotten increasingly difficult to express to patients," says Andrew L. Siegel, MD.

Over a decade of data document a continued increase in the use of hypofractionation in patients with localized prostate cancer.

Over the past year, the FDA approved a multitude of new treatments and devices for use in urology practice.